Development of novel viral vectored vaccines against Marburgviruses inducing rob...
Development of novel viral vectored vaccines against Marburgviruses inducing robust and cross-reactive protection
The frequency, magnitude, and geographical range of Marburg virus disease outbreaks are expanding, with recent cases emerging in Equatorial Guinea and Tanzania. Marburgviruses, listed among the WHO priority pathogens, have demonst...
The frequency, magnitude, and geographical range of Marburg virus disease outbreaks are expanding, with recent cases emerging in Equatorial Guinea and Tanzania. Marburgviruses, listed among the WHO priority pathogens, have demonstrated their epidemic potential. However, no licensed vaccines are available, and outbreaks continue to impose high morbidity and mortality burdens. Vaccine candidates in the pipeline are based on the Marburg virus (MARV) glycoprotein (GP) as a single immunogen. MARVAX ambition is to improve the strength and breadth of MARV vaccines by deploying the measles virus (MV) and modified vaccinia virus Ankara (MVA) viral vector vaccine platforms for expression of several MARV antigens: GP, viral protein 40 (VP40), which together with GP allows the formation of virus-like particles, and the nucleoprotein (NP), which contains conserved epitopes that are the main drivers of T cell responses. We will evaluate in depth the innate, adaptive and memory antigen-specific humoral and cellular cross-protective immune responses induced by MV-MARV and MVA-MARV vaccine candidates against MARV, Ravn virus and ebolaviruses, in single dose and in homologous and heterologous prime/boost immunization regimens, through an innovative preclinical testing pipeline. We will use cutting-edge and novel in vitro primary human cell co-cultures and immunocompetent mouse models to evaluate immunogenicity, chimeric and avatar mouse models to evaluate immunogenicity and efficacy and identify correlates of protection, and the highly relevant cynomolgus macaque model to evaluate safety, immunogenicity and efficacy. Furthermore, GMP batches of the best vaccine candidates will be produced by the end of the project, towards their future evaluation in a phase I clinical trial, in collaboration with the WHO-led initiative for prioritization and acceleration of clinical trials of Marburgvirus vaccines in at-risk and healthcare communities and upon outbreaks.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.